RMC-6291

Biorbyt

RMC-6291

10

Research Use Only

98.73%

C55H78FN9O8

1012.26

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1].

O=C(C#CC(N(C)C)(C)C)N1CCC(F)(C(=O)N(C)C(C(=O)NC2C(=O)N3NC(C(=O)OCC(C)(C)CC=4C5=CC(=CC=C5N(C4C=6C=CC=NC6C(OC)C)CC)N7CCOC(C7)C2)CCC3)C(C)C)CC1

-20°C

12352200